HOOKIPA PHARMA INC (HOOK)

Company Profile

HOOKIPA Pharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 151 full-time employees. The company went IPO on 2019-04-18. HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Company Info

HOOKIPA PHARMA INC

350 Fifth Avenue, 72Nd Floor, Suite 7240

New York City NEW YORK 10118

P: 114318906360

CEO: Joern Aldag

Employees: 151

Website: https://www.hookipapharma.com/